A new trading day began on Tuesday, with Cytokinetics Inc (NASDAQ: CYTK) stock price up 6.21% from the previous day of trading, before settling in for the closing price of $30.75. CYTK’s price has ranged from $29.31 to $61.40 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 44.31% over the last five years. Meanwhile, its annual earnings per share averaged -8.77%. With a float of $116.71 million, this company’s outstanding shares have now reached $119.22 million.
The firm has a total of 498 workers. Let’s measure their productivity. In terms of profitability, gross margin is -1359.51%, operating margin of -2943.3%, and the pretax margin is -3201.47%.
Cytokinetics Inc (CYTK) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Cytokinetics Inc is 2.27%, while institutional ownership is 116.07%. The most recent insider transaction that took place on May 20 ’25, was worth 63,960. In this transaction EVP Research & Development of this company sold 2,000 shares at a rate of $31.98, taking the stock ownership to the 140,255 shares. Before that another transaction happened on May 16 ’25, when Company’s President & CEO sold 5,000 for $30.93, making the entire transaction worth $154,650. This insider now owns 412,629 shares in total.
Cytokinetics Inc (CYTK) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -8.77% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 15.83% during the next five years compared to -20.02% drop over the previous five years of trading.
Cytokinetics Inc (NASDAQ: CYTK) Trading Performance Indicators
Here are Cytokinetics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 5.99. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 202.94.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.31, a number that is poised to hit -1.42 in the next quarter and is forecasted to reach -4.91 in one year’s time.
Technical Analysis of Cytokinetics Inc (CYTK)
Analysing the last 5-days average volume posted by the [Cytokinetics Inc, CYTK], we can find that recorded value of 2.17 million was better than the volume posted last year of 1.95 million. As of the previous 9 days, the stock’s Stochastic %D was 43.51%. Additionally, its Average True Range was 2.17.
During the past 100 days, Cytokinetics Inc’s (CYTK) raw stochastic average was set at 14.26%, which indicates a significant decrease from 23.73% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 72.49% in the past 14 days, which was higher than the 59.62% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $38.81, while its 200-day Moving Average is $48.11. Now, the first resistance to watch is $33.60. This is followed by the second major resistance level at $34.55. The third major resistance level sits at $36.05. If the price goes on to break the first support level at $31.15, it is likely to go to the next support level at $29.65. Should the price break the second support level, the third support level stands at $28.70.
Cytokinetics Inc (NASDAQ: CYTK) Key Stats
With a market capitalization of 3.90 billion, the company has a total of 119,427K Shares Outstanding. Currently, annual sales are 18,470 K while annual income is -589,530 K. The company’s previous quarter sales were 1,580 K while its latest quarter income was -161,380 K.
